BiotechTube
Araris Biotech

Araris Biotech

Schlieren, Switzerland· Est.
ararisbiotech.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $20M

Overview

Araris Biotech is developing a disruptive ADC linker technology designed to overcome key limitations of current ADC platforms, including heterogeneity, instability, and complex manufacturing. Its proprietary peptide linker attaches payloads site-specifically to a specific amino acid (Q295) in the antibody's Fc region, preserving antibody function and improving pharmacokinetics. The company has secured significant venture funding and established key partnerships with Taiho Oncology and Chugai Pharmaceutical, positioning it to advance its internal pipeline and out-license its platform technology.

Oncology

Technology Platform

Proprietary peptide linker technology (AraLinQ®) for site-specific, one-step conjugation of payloads to off-the-shelf antibodies via microbial transglutaminase, targeting glutamine Q295 in the Fc region to create homogeneous, stable, and soluble ADCs.

Funding History

2
Total raised:$20M
Series A$15M
Seed$5M

Opportunities

The rapidly expanding ADC market, valued in the tens of billions, presents a massive opportunity for a superior linker technology that improves homogeneity, stability, and manufacturability.
Araris's platform-agnostic approach allows for partnerships across multiple targets and payloads, generating significant potential for non-dilutive revenue through licensing deals.
Successful clinical validation could position the company as a leading ADC technology provider or an attractive acquisition target.

Risk Factors

The company faces high preclinical and clinical development risk, as its novel technology must prove safe and effective in human trials.
Competition in the ADC space is intense from both large pharmaceutical companies and well-funded biotechs.
As a private, preclinical firm, Araris remains dependent on raising additional capital to fund expensive clinical development, which may lead to shareholder dilution.

Competitive Landscape

Araris competes in the crowded ADC linker and conjugation technology space against established players like Seagen (now part of Pfizer), ImmunoGen, and Daiichi Sankyo, as well as other platform companies such as Mersana Therapeutics, Sutro Biopharma, and Ambrx. Its key differentiators are the one-step, off-the-shelf conjugation to a specific Fc site, which avoids antibody engineering, and the resulting homogeneous, stable product profile.

More companies in Antibody-Drug Conjugates →More companies in Switzerland →